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Objective: The proximal aortic neck remains one of the challenges of endovascular aneurysm repair (EVAR), and the risk
of type Ia endoleak and endograft migration is increased in patients with short, large-diameter, or highly angulated necks.
EndoAnchors have been used as an adjunct to EVAR in such patients, and the aim of this study was to assess their beneﬁt
analyzed by indication for use.
Methods: During a 2-year period, 319 patients were enrolled at 43 sites in the Aneurysm Treatment Using the Heli-FX
Aortic Securement System Global Registry (ANCHOR) study. This prospective, multinational, real-world analysis of
EndoAnchors comprised two groups of patients, those undergoing ﬁrst-time EVAR (primary arm, 242) and those with
proximal neck complications remote from the time of an initial endograft implantation (revision arm, 77). The primary
arm was further subdivided into patients undergoing prophylactic EndoAnchor use for hostile proximal neck anatomy
(178), with a type Ia endoleak evident during initial endograft deployment (60), and in conjunction with extender cuffs
after unsatisfactory endograft deployment distally in the neck (four). The revision arm was subdivided into patients
presenting with a type Ia endoleak alone (45), endograft migration alone (11), and migration with endoleak (21).
Technical success was site reported as satisfactory deployment of the desired number of EndoAnchors without fracture or
loss of integrity. Procedural success was deﬁned as technical success without type Ia endoleak at completion arteriography.
Core laboratory analysis was performed on 249 baseline and 192 follow-up computed tomographic studies, 66 of which
were available within the 1-year window.
Results: Technical and procedural success rates were highest in the prophylactically treated subset (172 of 178; 96.6%).
Whereas the technical success of EndoAnchor deployment was also high in the other subsets, residual type Ia endoleaks
were more frequent at completion angiography when the indication for EndoAnchor use was type Ia endoleak, both in
the primary arm (17 of 60; 28%) and in the revision arm (9 of 45; 20%). During a median imaging follow-up of 7 months,
183 of 202 patients (90.1%) remained free of type Ia endoleaks. Primary prophylactic patients were free from type Ia
endoleak in 110 of 114 cases (96.5%). The most challenging subset was revision patients treated for type Ia endoleak; type
Ia endoleaks were evident during follow-up in 10 of 29 of the cases (34%). Sac regression >5 mm in patients with 1-year
imaging was observed in 26 of 66 patients (39%) and was highest in the primary prophylaxis subset (20 of 43; 47%).
Conclusions: EndoAnchor implantation can be a useful adjunct to EVAR as prophylaxis against proximal attachment site
complications in patients with hostile aortic neck anatomy, as treatment for early and late type Ia endoleaks, or, in
conjunction with aortic extension cuffs, for endograft migration. Whereas the most challenging patients are those who
present with type Ia endoleaks remote from initial EVAR, EndoAnchors are still effective in treating the majority of these
cases. (J Vasc Surg 2014;60:1460-7.)Complications at the aortic neck represent one of the
remaining challenges of endovascular aneurysm repair
(EVAR).1-6 Type Ia endoleaks at the proximal attachment
site and loss of ﬁxation with endograft migration continue
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lenging neck anatomy and to treat these complications
when they arise.12 By deploying small helical anchors to
afﬁx an endograft to the aortic wall, EndoAnchors provide
a degree of sealing and ﬁxation that approximates the
strength of an open surgical hand-sewn anastomosis.13
The clinical outcome after EndoAnchor use for aortic
neck complications observed at the time of EVAR or
remote from the initial endovascular repair has been re-
ported in the aggregate in the Aneurysm Treatment Using
the Heli-FX Aortic Securement System Global Registry
(ANCHOR) study.12,14 Recent publications demonstrated
satisfactory short-term success with EndoAnchors.12,14-17
It is axiomatic that clinical results vary by the speciﬁc indi-
cation for EndoAnchor usedtype Ia endoleak, endograft
migration, or unsatisfactory distal deployment in the
neckdeither at the time of primary EVAR or during
follow-up. The current analysis was undertaken to assess
clinical and imaging outcome, analyzing results during
longer follow-up, segregated by the indication for
EndoAnchor use. Such information may be of value to
the clinician in weighing the risks and beneﬁts of EndoAn-
chor use in an individual patient with a speciﬁc clinical
presentation.
METHODS
The ANCHOR study is a prospective, nonrandomized,
dual-arm, multicenter, multinational postmarketing study
of the real-world use of the Heli-FX system with EndoAn-
chors in patients undergoing or who have undergone
EVAR for infrarenal abdominal aortic aneurysms. Partici-
pating investigators are listed in the Appendix (online only).
Study design. The ANCHOR study was registered on
ClinicalTrials.gov on February 9, 2012. Institutional Re-
view Board or Ethics Committee approval was obtained
at each site, and each patient provided written informed
consent. The study was conducted according to the Decla-
ration of Helsinki, applicable sections of ISO 14155,
MEDDEV 2.12-2, and the International Conference on
Harmonization Good Clinical Practice guidelines.
Patients with infrarenal abdominal aortic aneurysms
were eligible for inclusion in the registry if they were
asymptomatic, symptomatic, or presented with aneurysm
rupture; had adequate iliofemoral access suitable to accom-
modate a 16F sheath; and had a life expectancy of 1 year or
more. Commercially available endografts that underwent
successful testing for EndoAnchor compatibility included
the Zenith (Cook, Bloomington, Ind), the Excluder
(W. L. Gore, Flagstaff, Ariz), and the AneuRx, Talent, or
Endurant devices (Medtronic Vascular, Santa Rosa, Calif).
Patients were ineligible for inclusion in the study if they had
prior EndoAnchor implantation or signiﬁcant proximal
aortic neck thrombus or calciﬁcation. In addition to con-
senting patients preoperatively, patients could also be con-
sented within 30 days after EndoAnchor implantation.
Investigators were asked to enroll such patients before
the ﬁrst postoperative imaging study. This criterion was
designed to reduce (but not to eliminate) the potentialfor selection bias without losing data from patients with
unplanned use of the device.
The study population was enrolled into two cohorts: a
primary arm, with patients who underwent EndoAnchor
implantation during an initial EVAR procedure; and a revi-
sion arm, with patients who had EndoAnchor placement
remote from the initial EVAR procedure when the patient
presented with type Ia endoleak, endograft migration, or
both. Aortic extender cuffs were used in conjunction
with EndoAnchors at the discretion of the investigator,
usually when a signiﬁcant length of aortic neck was present
between the proximal margin of the endograft and the
lowest renal artery, either from misdeployment (primary
arm) or from postprocedure endograft migration (revision
arm). Patients were subcategorized into six subsets by indi-
cation for EndoAnchor use. Patients in the primary arm
included those with site-reported hostile aortic neck anat-
omy who were treated for prophylaxis against future neck
complications, type Ia endoleak after endograft deploy-
ment, or unsatisfactory endograft deployment distally in
the aortic neck. The last subset was deﬁned by the investi-
gator as unsatisfactory endograft deployment distally
within the aortic neck in the absence of discernible endo-
leak but requiring deployment of an extension cuff to
achieve an acceptable seal zone length. Patients in the revi-
sion arm were treated for type Ia endoleak, endograft
migration, or both. The current analysis categorizes eight
patients in the primary arm initially treated for hostile
neck anatomy but who exhibited a type Ia endoleak at
the time of endograft deployment within the primary endo-
leak subgroup and not in the prophylactic subgroup, in
contrast to prior publications.15
Study device. The Aptus Heli-FX EndoAnchor Sys-
tem and its method of use have been described in prior
publications, including photographs of EndoAnchors, the
delivery system, and deployment into the aortic
wall.12,13,15-17 The Heli-FX system was initially cleared by
the U.S. Food and Drug Administration in 2011 and is
indicated to provide ﬁxation and sealing between endo-
vascular aortic grafts and the native artery in patients whose
endovascular grafts have exhibited migration or endoleak or
are at risk of such complications and in whom augmented
radial ﬁxation or sealing is required to regain or to maintain
adequate aneurysm exclusion. The system is composed of
the Heli-FX Guide, EndoAnchors, and the Heli-FX
Applier. The system is intended to provide ﬁxation of an
endograft to the aortic wall. The Heli-FX Applier is passed
through the lumen of the Heli-FX Guide, and each 4.5-
mm-length, 3-mm-diameter helically shaped EndoAnchor
is implanted serially around the circumference of the
endograft within the proximal aortic neck. EndoAnchors
are deployed in a two-stage process that allows retraction of
an EndoAnchor and repositioning before ﬁnal deployment.
End points and deﬁnitions. For the purposes of this
analysis, the primary and revision treatment arms were sub-
categorized by the indication for EndoAnchor use. Patients
in the primary arm underwent EndoAnchor implantation
for one of three indications: (1) prophylaxis against
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endoleak, or (3) maldeployment of the endograft at an un-
satisfactory location distally in the neck. Patients in the revi-
sion arm were implanted with EndoAnchors for either type
Ia endoleak or endograft migration, accounting for three
subgroups: (1) patients with type Ia endoleak without
migration, (2) patients with endograft migration without
type Ia endoleak, and (3) those with both.
The index procedure was deﬁned as the initial proce-
dure with EndoAnchors implantation as part of the AN-
CHOR study. Index procedures within the primary arm
index were contemporaneous with EVAR. By contrast, in-
dex procedures in the revision arm were deﬁned as the
EndoAnchor procedure remote from the initial EVAR
and not the original endograft procedure itself. Site-
speciﬁed clinical end points included technical and proce-
dural success. Technical success was deﬁned when the
investigator determined that the desired number of
EndoAnchors were implanted, each with adequate penetra-
tion of the aortic wall and without EndoAnchor fracture.
Procedural success was deﬁned as technical success without
type Ia endoleak at completion angiography. Adverse event
reporting followed the recommendations speciﬁed by the
Society for Vascular Surgery reporting standards and guide-
line documents.18,19 Aneurysm-related reinterventions were
deﬁned as any reinterventionwithin 30days of the index pro-
cedure or any reintervention performed to address complica-
tions of the aneurysm, the endograft, or EndoAnchors.
EndoAnchor-related reinterventions were deﬁned as those
reinterventions performed for type Ia endoleak, endograft
migration, or EndoAnchor fracture or embolization.
Imaging studies. Follow-up was performed according
to each investigator’s standard of care. Societal guidelines
were recommended but not required, including computed
tomographic (CT) imaging with and without contrast
enhancement or without contrast enhancement but with
duplex ultrasonography at 30 days, at 12 months, and
annually thereafter. Endoleaks at completion arteriography
were site reported. Independent core laboratory analyses
(Syntactx, New York, NY) were performed on non-
contrast-enhanced and contrast-enhanced preoperative
and follow-up CT imaging studies. Centerline reformatting
and segmentation of CT data sets were performed with
iNtuition imaging software (TeraRecon, Foster City,
Calif). Imaging end points were measured and reported by
the methodology from the Society for Vascular Surgery
documents where available.18,19 The proximal aortic neck
length was calculated as the length where the aortic
diameter remained no more than 10% greater than the
immediate infrarenal diameter. Infrarenal neck angulation
was measured with centerline points at the level of the
lowest renal artery, at the distal aortic neck, and at the
aortic bifurcation. A conical proximal aortic neck was
deﬁned as one in which the aortic diameter increased more
than 10% from the lowest main renal artery to a point
10 mm distally. Aortic neck calcium and thrombus content
was measured and expressed in degrees of circumference
where its thickness exceeded 1 mm. Signiﬁcant muralthrombus or calcium was deﬁned when the average thick-
ness was >1 mm. The proximal aortic neck was considered
“hostile” when its length was less than 10 mm, diameter
exceeded 28 mm, angulation was more than 60 degrees, or
mural thrombus or calcium exceeded 1 mm in average
thickness or when the aortic neck was conical. For the
purposes of analysis, the 1-year imaging study was speciﬁed
with a window of 360 6 90 days.
Data analysis. An electronic data capture system was
used (iMedNet, Minnetonka, Minn). Electronic case
report forms were veriﬁed and electronically signed by
each investigator. All elements of the case report forms
were remotely monitored by independent clinical moni-
tors. Safety end points were evaluated by an independent
medical monitor, both in individual listings and in sum-
mary table format. The medical monitor identiﬁed any
unanticipated adverse device effects that by virtue of
severity or incidence, individually or in the aggregate,
were not previously described.19
This was not a hypothesis-driven study, and for this
reason, no sample size calculation was performed. Contin-
uous variables are expressed as mean and standard devia-
tion or, when not normally distributed, as median and
interquartile range. Dichotomous end points were calcu-
lated as a numerator deﬁned as the number of subjects trig-
gering the end point, divided by a denominator deﬁned as
the number of subjects with the end point available for
analysis. Differences in continuous variables were evaluated
with the Student t-test or single-factor analysis of variance.
Dichotomous variables were assessed with Fisher exact test
when individual cell numbers were <5 and with a standard
c2 analysis when not. P values were considered to be signif-
icant when the two-tailed a was < .05, and Bonferroni cor-
rections were used for multiple comparisons.
RESULTS
Between February 2012 and December 2013, 319 pa-
tients from 43 sites in the United States and Europe were
enrolled in the ANCHOR study. Among these, 242 patients
(75.8%)were primary cases and77 (24%)were revisions. The
number of patients per site ranged from one to 59 (mean,
7 6 11). The baseline patient characteristics have been re-
ported previously. In brief, patients had intact aneurysms
in 99% of the cases and were most commonly American So-
ciety of Anesthesiologists physical status class 3 (71.5%) or
class 4 (18.5%). Core laboratory-assessed baseline anatomic
characteristics conﬁrmed a hostile aortic neck in 84.1% of
patients. The proximal neck was <15 mm in length in
57.4% and <10 mm in length in 39.5%.
Baseline characteristics. Demographic characteristics
were similar in the primary and revision arms, but there
were signiﬁcant differences by indication (Table I). The
proportion of different endografts also varied between
indication subsets (Table II). The most common endograft
in the primary arm was the Medtronic Endurant (46.3%).
Endografts were more homogeneously distributed in the
revision arm, with no one device representing more than
25% of the group.
Table I. Baseline demographics by indication for EndoAnchor use (P values are speciﬁed in footnotes only for signiﬁcant
differences after Bonferroni correction)
Demographic variable
Primary arm indication Revision arm indication
Prophylaxis Type Ia endoleak Endograft maldeploymenta Type Ia endoleak Migration Endoleak and migration
No. 178 60 4 45 11 21
Age, years 72 6 8 75 6 8 76 6 6 77 6 7 75 6 7 79 6 8b
Male gender 138 (77.5) 38 (63) 4 (100) 33 (73) 10 (91) 15 (71)
Height, cm 172 6 16 171 6 26 178 6 13 171 6 9 180 6 9 173 6 8
Weight, kg 84.3 6 20.4 80.2 6 15.7 74.1 6 7.0 79.4 6 18.9 94.5 6 17.6 90.2 6 18.7
Body mass
index, kg/m2
28.1 6 5.8 26.8 6 4.9 23.6 6 2.8 26.9 6 5.4 29.2 6 5.8 30.2 6 6.2
Continuous data are presented as mean 6 standard deviation and categorical data as number (%).
aNo statistical testing was performed with respect to this group because of the small number of patients.
bP ¼ .002 vs primary prophylaxis subset; P < .001 vs revisions for endoleak.
Table II. Types of endografts (231 patients with data; percentage indicates the proportion of endografts within a row)
Indication subset Endurant, No. (%)Talent, No. (%)AneuRx, No. (%)Zenith, No. (%)Excluder, No. (%)Other, No. (%)
Primary 112 (46.3) 0 0 39 (16.1) 86 (35.5) 5 (2)
Prophylactic 90 (50.6) 0 0 27 (15.2) 58 (32.6) 3 (2)
Type Ia endoleak 18 (30.0) 0 0 12 (20.0) 28 (46.7) 2 (3)
Distal endograft misdeployment 4 (100) 0 0 0 0 0
Revision 10 (13) 14 (18) 18 (23) 11 (14) 16 (21) 8 (10)
Type Ia endoleak 9 (20) 8 (18) 5 (11) 8 (18) 11 (24) 4 (9)
Endograft migration 0 2 (18) 5 (45) 0 3 (27) 1 (9)
Endoleak and migration 1 (5) 4 (19) 8 (38) 3 (14) 2 (10) 3 (14)
All 122 (38.2) 14 (4.4) 18 (5.6) 50 (15.7) 102 (32.0) 13 (4.1)
Table III. Baseline anatomic characteristics (core laboratory analysis of 249 adequate preoperative imaging studies) by
indication for EndoAnchor use
Anatomic measure
Primary arm indication Revision arm indication
Prophylaxis
Type Ia
endoleak
Endograft
maldeployment
Type Ia
endoleak Migration
Endoleak and
migration
Images available for core
laboratory, No.
138 48 3 37 8 15
Maximum sac diameter, mm 55 6 11 56 6 11 60 6 8 69 6 18 67 6 17 65 6 10
Suprarenal aortic diameter, mm 27 6 3 27 6 3 26 6 3 30 6 6 34 6 7 31 6 6
Infrarenal aortic neck
diameter, mm
26 6 4 26 6 5 27 6 7 29 6 9 29 6 3 32 6 7
Infrarenal neck length, mm 17 6 13 17 6 9 6 6 3 13 6 10 19 6 13 17 6 14
Suprarenal angulation, degrees 16 612 19 6 15 11 6 6 14 6 9 15 6 14 13 6 9
Infrarenal angulation, degrees 34 6 18 40 6 19 36 6 24 37 6 16 32 6 8 38 6 19
Neck thrombus, mm 0.9 6 1.4 0.3 6 0.7 0.6 6 1.1 1.4 6 4.6 0.7 6 1.1 0.9 6 2.8
Neck thrombus, degrees
circumference
57 6 83 21 6 46 71 6 124 47 6 91 51 6 80 22 6 62
Neck calcium, mm 1.1 6 1.3 1.1 6 1.2 1.8 6 0.9 0.3 6 0.9 0 6 0 0.7 6 1.2
Neck calcium, degrees
circumference
22 6 32 28 6 44 22 6 5 3 6 9 0 6 0 12 6 24
Conical conﬁguration 53 (38.4) 14 (29) 3 (100) 18 (49) 2 (25) 7 (47)
Hostile neck 118 (85.5) 39 (81) 3 (100) 28 (76) 6 (75) 15 (100)
Data are presented as mean 6 standard deviation.
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for EndoAnchor use (Table III). Aneurysm sac diameter
was greater in the revision arm (68 6 17 vs 56 6
12 mm; P < .001), as was proximal neck diameter (30 6
7 vs 26 6 4 mm; P < .001). Mural calcium within theproximal neck was greater in the primary arm, with
2 mm or more of mural calcium covering 23 6 34 vs
5 6 16 degrees of neck circumference (P < .001). Differ-
ences in neck length, angulation, mural thrombus content,
or the frequency of a conical conﬁguration were not
Table IV. Details of the index procedure and the initial hospitalization
Measure
Primary arm indication Revision arm indication
Prophylaxis
Type Ia
endoleak
Endograft
maldeploymenta
Type Ia
endoleak Migration
Endoleak and
migration
No.b 178 60 4 45 11 21
Number of EndoAnchors deployed 5.3 6 1.7c 6.2 6 2.0 5.8 6 1.5 7.0 6 2.5 6.0 6 2.2 6.3 6 2.6
Procedure duration, minutes 129 6 66d 165 6 81 138 6 69 129 6 52 123 6 75 194 6 116
Fluoroscopy use, minutes 30 6 13 34 6 16 35 6 19 20 6 8e 36 6 18 34 6 18
Technical success 172 (96.6) 59 (98) 2 (50) 43 (96) 8 (73) 19 (90)
Procedural success 172 (96.6) 43 (72) 2 (50) 35 (78) 8 (73) 19 (90)
Type Ia endoleak at end of proceduref 0 (0) 17 (28) 1 (25) 9 (20) 0 (0) 1 (5)
Intensive care unit, % admitted 37.7 27 100 23 50 48
Length of hospitalization, days 3.9 6 7.0 4.0 6 4.9 4.0 6 2.3 7.0 6 8.8 2.1 6 1.3g 7.3 6 9.6
Continuous data are presented as mean 6 standard deviation and categorical data as number (%).
aNo statistical testing was performed for this subgroup because of the small number of patients.
bData on ﬂuoroscopy, intensive care unit admission, and length of hospitalization are based on less than the speciﬁed number because of missing values.
cP ¼ .001 vs primary endoleak subset; P < .001 vs revisions for endoleak subset.
dP ¼ .002 vs primary prophylactic subset.
eP < .001 vs primary prophylaxis and primary endoleak subsets.
fSite-reported type Ia endoleaks on completion angiography after deployment of EndoAnchors. Another endoleak was initially reported to be present after
EndoAnchor deployment, but on site monitoring, the endoleak was present before but not after deployment.
gP ¼ .001 vs revisions for endoleak subset.
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anatomy met the criteria for a hostile neck in 160 of 189
(84.7%) and 49 of 60 (82%) of the primary and revision pa-
tients, respectively (P ¼ .727). Within the six subsets of in-
dications for EndoAnchor use, the aortic neck length was
shortest in the primary arm patients with unsatisfactory
distal endograft deployment (5.5 mm) and in the revision
patients with endoleaks (13.5 mm).
Index procedure and hospitalization. Details of the
index procedure and hospitalization appear in Table IV.
A mean of 5.8 6 2.1 EndoAnchors was deployed, 5.5 6
1.8 in the primary arm and 6.7 6 2.5 in the revisions (P <
.001). The number of EndoAnchors deployed differed
signiﬁcantly between indication subsets (P< .001), with the
fewest EndoAnchors deployed in patients treated prophy-
lactically (5.3 6 1.7) and the greatest number of EndoAn-
chors in the revision patients treated for endoleak (7.0 6
2.5). Fewer EndoAnchors were deployed in patients with
procedural success, 5.5 6 1.9 vs 7.6 6 2.5 (P < .001). The
duration of the index procedure was similar in the primary
and revision arms (P ¼ .632) but did differ signiﬁcantly by
indication subset (P < .001). Procedure duration was
longest in the revisions treated for migration and endoleak
(1946 116minutes) and shortest in the revisions treated for
endoleak alone (123 6 75 minutes). Fluoroscopy time was
similar in the primary and revision arms (P ¼ .202) but was
associated with indication subset and was shortest in the
revisions treated for endoleak alone (20 6 8 minutes). Suc-
cess rates were uniformly high, with signiﬁcantly higher
procedural success in the primary arm (P ¼ .035). There
were signiﬁcant differences between the indication subsets,
with a lower rate of technical and procedural success when
migration was present (P < .001). There were 28 type Ia
endoleaks reported by the sites at the conclusion of the index
procedure, and they weremost frequent when the indicationfor EndoAnchor use was endoleak. Among these, 17
(60.7%) were resolved on the ﬁrst postoperative core labo-
ratory-assessed CT scan. Patients with type Ia endoleaks
at completion angiography had their ﬁrst postoperative
CT study earlier than those without endoleaks, 20 618 vs
416 36 days after the index procedure (P ¼ .013).
The length of hospitalization averaged 4.5 6 7.1 days,
3.9 6 6.5 days in the primary arm and 6.4 6 8.5 days in
the revision arm (P ¼ .026). The length of hospitalization
was associated with the indication for EndoAnchors (P ¼
.050), ranging from 2.1 6 1.3 days in revision cases treated
for migration to 7.0 6 8.8 days in revisions treated for
endoleak alone and 7.3 6 9.6 days in revisions treated
for endoleak with migration.
Postoperative follow-up. Clinical follow-up averaged
16 6 5 months and did not differ between indications for
EndoAnchor use (Table V). There were no signiﬁcant
differences in the frequency of serious adverse events (P ¼
.416; Table VI) or all-cause mortality (P ¼ .434) within the
different indications for EndoAnchor use. Serious adverse
events occurred in 43 patients (17.8%) in the primary arm
and 18 patients (23.4%) in the revision arm (P ¼ .276).
The subset with the lowest frequency of serious adverse
events was the primary prophylaxis group (15.6%), and the
subset with the highest rate of serious adverse events was
the revision patients treated for endoleak (33.3%). Renal
insufﬁciency developed in 10 patients (3%). Deaths
occurred in 15 patients (4.7%) in the series, and none were
device related. One death was procedure related, occurring
within 30 days of the index procedure. This patient expe-
rienced perioperative bleeding complications unrelated to
EndoAnchor use and expired on postoperative day 12 from
multiorgan system failure.
There were 33 aneurysm-related reinterventions occur-
ring in 22 (6.9%) of the 319 study patients. Among the
Table V. Clinical outcome during follow-up
Indication for
EndoAnchor use No.
Follow-up,
mean 6 SD, months
Serious adverse
events,a No. (%)
All-cause
death, No. (%)
Aneurysm-related
reinterventions,b No. (%)
EndoAnchor-related
reinterventions, No. (%)
Primary 242 16 6 5 43 (17.8) 11 (4.5) 11 (4.5) 2 (2.2)
Prophylaxis 186 16 6 5 29 (15.6) 7 (4) 8 (4) 0 (0)
Type Ia endoleak 52 15 6 5 13 (25) 3 (5) 3 (5) 2 (3)
Endograft maldeployment 4 17 6 6 1 (25) 1 (25) 0 (0) 0 (0)
Revision 77 16 6 6 18 (23) 4 (5) 11 (14) 5 (6)
Migration 11 17 6 5 1 (19) 0 (0) 3 (27) 0 (0)
Type Ia endoleak 45 17 6 6 10 (22) 3 (7) 6 (13) 4 (9)
Migration and endoleak 21 16 6 6 7 (33) 1 (5) 2 (10) 1 (5)
All 319 16 6 5 61 (19.1) 15 (4.7) 22 (6.9) 7 (2)
SD, Standard deviation.
aSerious adverse events are tabulated by patient. The percentage denotes the proportion of patients within a subgroup who experienced an event.
bThe number of aneurysm-related reinterventions is tabulated by patient; a patient who had more than one reintervention is listed only once. All EndoAnchor-
related reinterventions are also aneurysm-related reinterventions.
Table VI. Serious adverse events
Category No. of events (%)
Vascular
Access vessel injury 3 (5)
Endograft limb occlusion 1 (2)
Lower extremity ischemia 7 (11)
Renal artery stenosis/renal embolus 3 (5)
Rupture thoracic aortic aneurysm 1 (2)
Respiratory
Pneumonia 2 (3)
Respiratory failure 4 (7)
Endoleaks
Type Ia endoleak 2 (3)
Type II endoleak 2 (3)
Type III endoleak 1 (2)
Cardiac
Myocardial infarction 2 (3)
Congestive heart failure 4 (7)
Arrhythmia 1 (2)
Neurologic
Stroke 2 (3)
Paraparesis 1 (2)
Other
Bleeding at operative site 7 (11)
Urologic 3 (5)
Gastrointestinal 4 (7)
Local wound complications 1 (2)
Fever 1 (2)
Other, unrelated 9 (15)
All serious adverse events 61 (100)
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II endoleak, and four for endograft limb occlusion.
Aneurysm-related reinterventions were more frequent in
the revision arm (11 of 77; 14.3%) compared with primary
cases (11 of 242; 4.5%; P ¼ .008). A patient who was
enrolled with a type Ia endoleak remote from initial
endograft implantation had persistence of the endoleak
despite repeated percutaneous interventions. This patient
eventually underwent open surgical conversion 1 year
after EndoAnchor implantation. CT imaging revealed an
undersized endograft with a 4-mm gap between the graft
and the wall of the proximal neck. There were 15
EndoAnchor-related reinterventions in seven patients(2%). The frequency of EndoAnchor-related reinterven-
tions was higher in the revision arm (5 of 77; 6%) than in
the primary arm (2 of 242; 1%; P ¼ .010).
Type Ia endoleaks were observed in 19 of the 202
patients (9.9%) with CT imaging assessed by the core lab-
oratory (mean imaging follow-up, 7 6 6 months;
Table VII). The highest rate of type Ia endoleak on
follow-up CT occurred in the subset of revision patients
with type Ia endoleak as the indication for EndoAnchors
use, with an observed frequency of 10 of 29 (34%). The
primary patients undergoing prophylactic use of Endo-
Anchors had the lowest rate of type Ia endoleaks in follow-
up, occurring in four of 114 patients (4%). Aneurysm sac
diameters were available in 66 patients with 1-year follow-
up CT imaging available. Sac regression of >5 mm was
observed in 26 patients (39%). The frequency of aneurysm
sac regression was highest when EndoAnchors were placed
for prophylaxis of aortic neck complications, occurring in
20 of the 43 patients in that subset (47%). When analyzed
by sac diameter change per month of observation, the
average change was 0.12 mm/month with a high degree
of variability (standard deviation, 1.3 mm/month) and
without statistical difference between the six indication sub-
sets (P ¼ .219). Aneurysm sac enlargement was observed in
one case (one of 66; 2%). This patient was in the revision arm
and presented with endograft migration. Despite deploy-
ment of an aortic extension cuff and EndoAnchors, CT im-
aging at 10 months after the procedure documented 6 mm
of sac enlargement without appreciable endoleak.
DISCUSSION
Since the advent of EVAR by Parodi with the ﬁrst ﬁve
cases reported in 1991, devices have undergone consider-
able technologic development. The ﬁeld has witnessed
signiﬁcant improvements in metallic materials and their
preparation, fabrics, methods of afﬁxing fabric to the stent
skeleton, and size and ease of use of delivery systems. In
parallel, there have been improvements in operator skills
and availability of better imaging equipment. Singularly
and in concert, the evolution of device design and clinical
care has enhanced the safety and durability of the procedure.
Table VII. Imaging outcome (core laboratory reported; 202 follow-up imaging studies)
Indication for EndoAnchor use
Follow-up, mean 6 SD,
months
Type Ia
endoleak, n/N (%)
Endograft
migration
Sac regression
(>5 mm),a n/N (%)
Sac enlargement
(>5 mm),a n/N (%)
Primary 7.1 6 5.5 8/158 (5) 0 22/52 (42) 0/52 (0)
Prophylaxis 7.4 6 5.9 4/114 (4) 0 20/43 (47) 0/43 (0)
Type Ia endoleak 5.9 6 3.9 4/41 (10) 0 2/8 (25) 0/8 (0)
Endograft maldeployment 7.3 6 6.2 0/4 (0) 0 0/1 (0) 0/1 (0)
Revision 7.3 6 5.7 11/44 (25) 0 4/14 (29) 1/14 (7)
Endograft migration 8.4 6 5.6 0/6 (0) 0 0/3 (0) 1/3 (33)
Type Ia endoleak 6.7 6 6.2 10/29 (34) 0 2/8 (25) 0/8 (0)
Migration and endoleak 8.3 6 4.5 1/9 (11) 0 2/3 (67) 0/3 (0)
All 7.1 6 5.6 19/202 (10) 0 26/66 (39) 1/66 (2)
SD, Standard deviation.
aTabulated for 66 patients with available 1-year computed tomography (CT) imaging studies.
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occur after EVAR. The rate of type Ia endoleak and endog-
raft migration, albeit reduced during the last two decades,
remains signiﬁcant in patients with hostile proximal neck
anatomy.20 As well, inadvertent deployment of an endog-
raft distally within the aortic neck occasionally occurs,
whether from inadequate imaging during release or as a
result of distal slippage within a conical neck. These com-
plications occur at a higher rate in a real-world clinical
use compared with the initial trials for regulatory approval,
an observation that may be related to off-label use in pa-
tients with challenging aortic anatomy.21,22 The frequency
of proximal neck complications may be inﬂuenced by de-
vice design improvements, advances that may embolden
clinicians to treat more anatomically challenging cases.23
We previously reported the intermediate-term outcome
of the ANCHOR trial in the aggregate.15 The current
report comprises a closer evaluation of outcome in six spe-
ciﬁc indications for EndoAnchor use with additional
follow-up. Among these, all but the primary prophylactic
subset encompass EndoAnchor use to treat an existing
problem: type Ia endoleak, unsatisfactory position of an
endograft, or both. The outcome after EndoAnchors use
in the primary prophylaxis subset was excellent, but it is clear
that their ultimate utility cannot be assessed without the
availability of longer term follow-up data. The risk of endog-
raft complications at the proximal neck increases over time,
and the current intermediate-term follow-up is insufﬁcient
for deﬁnitive conclusions to be drawn. By contrast, the util-
ity of EndoAnchors for treatment of existing complications
may be at least in part assessable with shorter follow-up.
Whereas the rate of recurrent endoleak and migration may
increase over time, the ﬁnding of successful intermediate-
term remediation of existing problems is promising.
The current analysis focused on the six general cate-
gories of indication for EndoAnchor use. Among the three
indication subsets in the primary arm, the best results were
achieved in the prophylaxis subgroup. Although the ulti-
mate value of EndoAnchors in the prevention of long-
term complications will require longer follow-up data, the
observed 3.5% rate of type Ia endoleak is lower than the
10% rate reported in prior studies.5,6,24 As well, the
ANCHOR study used core laboratory CT assessment ofendoleaks, whereas prior series were, by and large, limited
to site-reported imaging ﬁndings. Thus, differences in
outcome must be considered in the context of the different
populations studied and end point deﬁnitions.
In patients with type Ia endoleaks evident on angiog-
raphy after endograft deployment, EndoAnchors resulted
in resolution of the endoleak in approximately 90% of cases.
EndoAnchor use as an adjunct to aortic extension cuff
deployment in patients with endograft maldeployment
distally in the neckwas uniformly successful, but only four pa-
tients fell within this indication. These patients represented a
small subset with an extreme degree of neck hostility.
In the revision arm, three indication subsets comprised
those with endograft migration, type Ia endoleak, or both,
treated remote from the initial EVAR procedure. Newer
generation devices appeared less often in the subgroup of pa-
tients presenting with both endoleak and migration.
Whereas this observation prompts consideration of endoleak
withmigration as a device-related event, one cannot exclude
longer follow-up as the explanation for the ﬁnding. These
subsets are characteristically among the most difﬁcult to
treat, often having failed numerous prior reinterventions,
with EndoAnchor use as a ﬁnal effort for cure. Fenestrated
and branched endografts offer one potential solution in
such patients, but the use of the only U.S. Food and Drug
Administration-approved fenestrated device is restricted by
angulation (<45 degrees) and neck length ($4 mm).25 A
recent series from the Cleveland Clinic reported on the use
of fenestrated and branched endografts in 54 patients pre-
senting with proximal neck failure remote from EVAR,11
somewhat analogous to the ANCHOR revision arm. The
fenestrated and breached endograft procedures were com-
plex, with an average duration of approximately 5 hours
and requiring 93mL of contrast material use and 83minutes
of ﬂuoroscopy, in each case, two to three times what was
observed in the ANCHOR revision subgroup. Technical
deployment failures occurred in 15% of patients. Type Ia
endoleaks were uncommon after fenestrated or branched
rescues, occurring in only one patient (2%). However, renal
insufﬁciency developed in 10% of patients, and secondary in-
terventions were required in 29% of the series.
Resolution of proximal endoleaks was observed in all
but one of the 15 patients with core laboratory imaging
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for migration with or without endoleak. The subset of
revision patients treated for type Ia endoleak alone was
perhaps the most challenging. These patients had very
short neck lengths, with almost half below 10 mm in
length. More important, these patients demonstrated
endoleaks in the presence of satisfactory endograft position
within the aortic neck. Despite the inability to effectively
address any diameter mismatch between an endograft
and neck diameter, approximately two thirds of these pa-
tients were effectively treated with EndoAnchors without
residual or recurrent proximal endoleaks in follow-up.
CONCLUSIONS
EndoAnchors can be a useful adjunct to EVAR in
treating postoperative complications that arise during or
after endograft implantation and for prophylaxis in patients
with challenging aortic neck anatomy. Whereas Endo-
Anchors can be effectively used to treat late type Ia endoleaks
remote from EVAR, the success rate is lower than when
such leaks are identiﬁed and treated with EndoAnchors
at the time of the initial aneurysm repair.
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